Innovation Grants to Nurture Initial Translational Efforts (IGNITE): Neurotherapeutic Agent Characterization and In vivo Efficacy Studies (R61/R33 Clinical Trial Not Allowed)
Grant Notice from a government agency.
Data as of Oct 24, 2026. Sources: SAM.gov and Grants.gov. Snapshot govcon-directory-20261024T104923Z-2151694.
This product uses the Grants.gov API but is not endorsed or certified by the U.S. Department of Health and Human Services. Counts and totals are computed by DSE from public SAM.gov and Grants.gov notices. Text from Grants.gov may be shortened or have contact details removed. The original notice on Grants.gov is the authoritative version.
Closing in 361 days
Notice details
- Notice type
- Grant Notice
- Solicitation number
- PAR-25-225
- Posted
- Nov 4, 2024
- Response deadline
- Oct 20, 2027
- Source
- Grants.gov
Description
Reissue PAR-21-122. This NOFO provides funding to conduct pharmacodynamic, pharmacokinetic, and in vivo efficacy studies to demonstrate that proposed therapeutic agent(s) have sufficient biological activity to warrant further development to treat neurological or neuromuscular disorders that fall under the NINDS mission. Therapeutic agents include small molecules, biologics or biotechnology-derived products. This FOA is part of a suite of Innovation Grants to Nurture Initial Translational Efforts (IGNITE) to advance projects to the point where they can meet the entry criteria for the Blueprint Neurotherapeutics Network or other translational programs.
Summarized from the official notice. Text from Grants.gov may be shortened or have contact details removed. The original notice on Grants.gov is the authoritative version.
Official notice
Requirements and amendments are controlled by the official notice.
DSE verdict
The DSE fit verdict for this notice is available to DSE GovCon subscribers. It is not published on this page.
See DSE GovCon plans →Get free alerts
Email alerts for notices like this one are free on DSE GovCon Intelligence.
Set up free alerts →